The
global Urinary
Tract Infection Testing Market is expected to reach USD 812.01 million
by 2030, according to a new report by Grand View Research, Inc. The market is
anticipated to grow at a CAGR of 4.4% from 2023 to 2030. The urinary tract
infection (UTI) testing market is witnessing growth due to factors such as
rising disease burden, increasing geriatric population, rapid technological
advancements, and high R&D investments by key players to introduce novel
& innovative products, such as self-testing & rapid Point-of-Care (PoC)
devices products.
Urinary
tract infection is becoming a common global concern. According to research
studies, UTI occurs in one in five adult women at some point in their life. In
the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. In the U.S.,
about 250,000 cases of pyelonephritis are reported every year. In women aged
18-19, its incidence is about 28/10,000, out of which 7% of cases require
hospital admission. Genetic and cultural factors may influence its prevalence;
for instance, in South Korea, the incidence of pyelonephritis is around
59/10,000. Its recurrence is more common than other UTIs, with the recurrence
rate being 5.7% in men and 9% in women.
Patients
with diabetes are at increased risk of developing urinary tract infections such
as acute cystitis, and therefore, the increasing global prevalence of diabetes
is likely to contribute to cystitis growth. According to an NCBI article, type
2 diabetes raises UTI risk and patients with type 2 diabetes experience frequent
& severe UTIs. According to the International Diabetes Federation (IDF)
data from 2021, approximately 643 million individuals will have diabetes by
2030 and 783 million by 2045. Moreover, the estimated prevalence of
asymptomatic bacteriuria in diabetic females is 26%, compared to 6% in
nondiabetic females. Such factors are expected to boost the prevalence of
cystitis globally.
However,
due to the rise in awareness about such diseases, the demand for specialist
treatment has increased in recent years. According to the U.S. Department of
Health and Human Services, in the U.S., the number of practicing urologists in
2020 was 4.07 per 100,000 populations. The report further stated that due to
the rise in demand, a shortage of urologists was observed, which is likely to
exceed nearly 3,600 physicians by 2025. This can impede market growth in the
coming years. Moreover, COVID-19 has had a detrimental impact on the industry.
Individuals with UTIs have experienced substantial disruptions in testing and
emergency care.
Key
players are introducing novel products to strengthen their portfolios. For
instance, in September 2021, OpGen, Inc. announced initiating clinical trials
of the Unyvero Urinary Tract Infection Panel. The panel can analyze a broad
range of pathogens and antimicrobial resistance markers directly from a urine
sample. Successful clinical trials and the launch of such technologically
advanced & efficient products are anticipated to drive market growth over
the coming years. Similarly, in July 2020, Uqora, Inc. (Pharmavite, LLC), a
urinary health biotechnology company, launched a UTI diagnostic and management
kit. The kit includes a rapid UTI diagnostic device, Clarify, compatible with a
PoC and homecare setting.
List of Key Players of Urinary Tract Infection Testing
Market
- QIAGEN
- Accelerate
Diagnostics, Inc.
- Bio-Rad
Laboratories, Inc.
- F.
Hoffmann-La Roche Ltd.
- Danaher
Corporation
- Siemens
Healthcare GmbH
- Randox
Laboratories Ltd.
- Thermo
Fisher Scientific, Inc.
- bioMérieux
SA
- T2
Biosystems, Inc.
Related Press
Release@ Urinary
Tract Infection Testing Market Report
Urinary Tract Infection Testing Market Highlights
- Cystitis
dominated the market in 2022, with an estimated market share of 41.42%.
This can be attributed to the high incidence & recurrence rate of
cystitis, increased number of product approvals, and the high number of
diabetes patients who are more prone to cystitis
- The
reference laboratories segment held a share of 26.66% in 2022 attributed
to the ongoing efforts of reference laboratories to enhance patient
outcomes by offering diagnostic facilities at retail level.
- North
America dominated the overall urinary tract infection market in terms of
value. This can be attributed to better reimbursement facilities and a
rise in the adoption of novel diagnostic products due to increased
awareness
Urinary Tract Infection Testing Market Segmentation
Grand
View Research has segmented the global urinary tract infection testing market
on the basis of type, end-use, and region:
Urinary Tract Infection Testing Type Outlook
(Revenue, USD Million, 2018 - 2030)
- Urethritis
- Cystitis
- Pyelonephritis
- Vaginitis
Urinary Tract Infection Testing End-use Outlook
(Revenue, USD Million; Volume, Units, 2018 - 2030)
- General
practitioners (GP's)
- Urologists
- Urogynecologists
- Accountable
Care Organization (ACO's)
- Hospital
Laboratories
- Reference
Laboratories
- Hospital
Emergency Departments
- Urgent Care
Urinary Tract Infection Testing Regional Outlook
(Revenue, USD Million, Volume, Units, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
and Africa (MEA)
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment